Empagliflozin for Kidney Disease in African American Veterans
This study is looking at how Empagliflozin (a medication) affects kidney health in African American veterans with chronic kidney disease that is not caused by diabetes. Researchers want to see if Empagliflozin 10 mg taken daily for 4 months can change specific proteins in your urine that are signs of kidney damage. These proteins, like nephrin and podocalyxin, are found in special kidney cells called podocytes. The study will compare Empagliflozin to a placebo (a pill with no medicine). To join, you must be an African American veteran between 19 and 90 years old with certain kidney function levels (eGFR) and a BMI between 18 and 39.9. The study aims to enroll 60 participants.
- Study design
- This is an interventional study comparing Empagliflozin to a placebo. It plans to enroll 60 participants.
- What's involved
- Participants will take either Empagliflozin 10 mg or a placebo orally daily for 4 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, which measures kidney dysfunction and podocyte specific injury, will be assessed at 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
At a glance
Conditions
NCT06110130
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Washington DC Veterans Affairs Medical Center (688)
Washington D.C., District of Columbiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Sabyasachi Sen, MD · PRINCIPAL_INVESTIGATOR · Washington VA Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To study kidney dysfunction and podocyte specific injury3 years
To study kidney dysfunction and podocyte specific injury in African American Veterans with Non-diabetic kidney disease, following low dose of Empagliflozin therapy. Empagliflozin may be referred to as "Empa" hereafter. Correlate changes in exosome-based podocyte specific proteins with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR.